Skip to main content
Search
Main content
Nature biomedical engineering
Published

Large-scale visualization of α-synuclein oligomers in Parkinson's disease brain tissue

Authors

Rebecca Andrews, Bin Fu, Christina E Toomey, Jonathan C Breiter, Joanne Lachica, Joseph S Beckwith, Ru Tian, Emma E Brock, Lisa-Maria Needham, Gregory J Chant, Camille Loiseau, Angèle Deconfin, Kenza Baspin, Rebeka Popovic, James Evans, Yen Goh, Begüm Kurt, Lenart Senicar, Marisa Edmonds, Tim Bartels, Nora Bengoa-Vergniory, Peter J Magill, Zane Jaunmuktane, Oliver J Freeman, Benjamin J M Taylor, John Hardy, Tammaryn Lashley, Mina Ryten, Michele Vendruscolo, Nicholas W Wood, Lucien E Weiss, Sonia Gandhi, Steven F Lee

Abstract

Nat Biomed Eng. 2025 Oct 1. doi: 10.1038/s41551-025-01496-4. Online ahead of print.

ABSTRACT

Parkinson's disease (PD) is a neurodegenerative condition characterized by the presence of intraneuronal aggregates containing fibrillar ɑ-synuclein known as Lewy bodies. These large end-stage species are formed by smaller soluble protein nanoscale assemblies, often termed oligomers, which are proposed as early drivers of pathogenesis. Until now, this hypothesis has remained controversial, at least in part because it has not been possible to directly visualize nanoscale assemblies in human brain tissue. Here we present Advanced Sensing of Aggregates-Parkinson's Disease, an imaging method to generate large-scale α-synuclein aggregate maps in post-mortem human brain tissue. We combined autofluorescence suppression with single-molecule fluorescence microscopy, which together enable the detection of nanoscale α-synuclein aggregates. To demonstrate the use of this platform, we analysed ~1.2 million nanoscale aggregates from the anterior cingulate cortex in human post-mortem brain samples from patients with PD and healthy controls. Our data reveal a disease-specific shift in a subpopulation of nanoscale assemblies that represent an early feature of the proteinopathy that underlies PD. We anticipate that quantitative information about this distribution provided by Advanced Sensing of Aggregates-Parkinson's Disease will enable mechanistic studies to reveal the pathological processes caused by α-synuclein aggregation.

PMID:41034512 | DOI:10.1038/s41551-025-01496-4

UK DRI Authors

Tim Bartels

Dr Tim Bartels

Group Leader

Untangling protein structure to better understand function and treat neurodegeneration

Dr Tim Bartels
John Hardy

Prof Sir John Hardy

Group Leader

Harnessing genetics to build a better understanding of dementia

Prof Sir John Hardy
Mina Ryten

Prof Mina Ryten

Centre Director

Leveraging brain transcriptomics to understand the pathophysiology of Lewy body diseases

Prof Mina Ryten